{'fraction_non_alphanumeric': 0.030710172744721688, 'fraction_numerical': 0.011516314779270634, 'mean_word_length': 6.352112676056338, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Impact of the CYP2D6 genotype on post‐operative intravenous oxycodone analgesia

Background: Oxycodone is a semi‐synthetic opioid with a μ‐receptor agonist‐mediated effect in several pain conditions, including post‐operative pain. Oxycodone is metabolized to its active metabolite oxymorphone by O‐demethylation via the polymorphic CYP2D6. The aim of this study was to investigate whether CYP2D6 poor metabolizers (PMs) yield the same analgesia post‐operatively from intravenous oxycodone as extensive metabolizers (EMs).